LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.